Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GS-9911 |
| Synonyms | |
| Therapy Description |
GS-9911 is a DGK-alpha inhibitor, which may increase TCR signaling and enhance antitumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GS-9911 | GS 9911|GS9911 | GS-9911 is a DGK-alpha inhibitor, which may increase TCR signaling and enhance antitumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06082960 | Phase I | GS-9911 + Zimberelimab GS-9911 | Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors | Active, not recruiting | USA | CAN | AUS | 0 |